Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
HCW Biologics Inc
HCWBHCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida. Address: 2929 North Commerce Parkway, Miramar, FL, United States, 33025
Analytics
Precio Objetivo de WallStreet
3 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave HCWB
Análisis de dividendos HCWB
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout HCWB
Valoración de la acción HCWB
Finanzas HCWB
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |